{"id":267,"date":"2023-05-13T10:00:00","date_gmt":"2023-05-13T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=267"},"modified":"2025-09-09T06:34:40","modified_gmt":"2025-09-09T06:34:40","slug":"china-bd-2023-lanova-and-astrazeneca-enters-a-600-million-usd-license-on-gprc5d-adc-lm-305","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/267.html","title":{"rendered":"[China BD 2023] LaNova and AstraZeneca Enters a 600 million USD License on GPRC5D ADC LM-305"},"content":{"rendered":"\n<p>Announced Date: 2023-05-12 (May 12, 2023)<\/p>\n\n\n\n<p>Asset Name: LM-299<\/p>\n\n\n\n<p>Licensor (Seller): LaNova Medicines (LaNova) (China)<\/p>\n\n\n\n<p>Licensee (Buyer): AstraZeneca<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: antibody drug conjugate (ADC)<\/p>\n\n\n\n<p>Asset Target: G protein-coupled receptor, class C, group 5, member D (GPRC5D)<\/p>\n\n\n\n<p>Current Stage: pre-clinical stage<\/p>\n\n\n\n<p>Potential Indication:  relapsed\/refractory multiple myeloma<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>LaNova Medicines is eligible to receive:<\/p>\n\n\n\n<p>Upfront and near-term payments of up to $55 million,<\/p>\n\n\n\n<p>Additional development and commercial milestone payments of up to $545 million,<\/p>\n\n\n\n<p>Total up to $600 million.<\/p>\n\n\n\n<p>Tiered royalties on net sales worldwide.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.lanovamedicines.com\/en\/news-center\/press-release\/62.html\">LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate-LaNova News-LaNova Medicines<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of \u201cLaNova Medicines\u201c\uff0c\u793c\u65b0\u533b\u836f<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-05-12 (May 12, 2023) Asset Name: LM-299 Licensor (Seller): LaNova Medicines (LaNova) (China) Licensee &hellip; <a title=\"[China BD 2023] LaNova and AstraZeneca Enters a 600 million USD License on GPRC5D ADC LM-305\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/267.html\"><span class=\"screen-reader-text\">[China BD 2023] LaNova and AstraZeneca Enters a 600 million USD License on GPRC5D ADC LM-305<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-267","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=267"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/267\/revisions"}],"predecessor-version":[{"id":270,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/267\/revisions\/270"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}